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Abstract
Treatment strategies that target the immune system provide the opportunity for antitumor activity across multiple
cancer types, regardless of mutational status or tumor histology. While many of the initial advances in
immunotherapy have been in melanoma, the focus has now broadened to include many other solid as well as
hematological cancers. Different immunotherapeutic approaches are being evaluated across tumor types and their
various novel mechanisms of action and safety profiles offer the potential for a variety of combination regimens.
Ongoing and planned investigation of these immunotherapies, alone and in combination, represents the start of a
new chapter in our treatment of cancer and offers the hope of better outcomes for patients with a wide range of
cancers. Recent advances in the use of immune-based approaches to treat non-small-cell lung cancer, breast
cancer, ovarian cancer, gastrointestinal cancer, hepatocellular carcinoma, head and neck cancer and lymphoma
were discussed at the 2015 Spring and Winter meetings of the Campania Society of Oncology Immunotherapy
(SCITO) and are reported here.
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Background
Both innate and adaptive T cell-mediated immunity arms
are believed to play coordinated roles in cancer immune
surveillance. T lymphocytes have a critical role in cancer
development, with density of tumor-infiltrating T lympho-
cytes (TILs) being prognostic for improved outcomes in
various cancers, although evidence concerning their antigen
specificity and protective mechanisms of action is limited
[1, 2]. A conceptual model in which an adaptive T cell re-
sponse composed of both cytotoxic CD8+ T cells (CTLs)
and CD4+ Th1 cells control cancer progression has been
postulated, involving cytokine production and the
expansion and activation of cytotoxic CD8+ T cells [3].
Immunotherapeutic approaches in cancer have mostly
attempted to harness this adaptive T cell response.
The immune system, and in particular T lymphocyte
activity, is regulated by a balance of co-stimulatory and
co-inhibitory signals known as immune checkpoints.
Normally, these act to prevent autoimmunity and dam-
age to peripheral tissues during immune responses to
infection. However, during tumour development, cancer
cells can utilize immune checkpoint proteins to suppress
and evade immune attack, resulting in unchecked tumor
progression. Cytotoxic T-lymphocyte-associated protein-4
(CTLA-4) and programmed cell death protein 1 (PD-1)
are checkpoint molecules that down-regulate T-cell activa-
tion pathways, thereby promoting tumour growth and
proliferation. Inhibition of CTLA-4 and PD-1 binding to
their ligands enhances T-cell activation and proliferation,
leading to tumor infiltration by T-cells and tumor regres-
sion [4].
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Recent advances in the use of immune-based ap-
proaches to treat cancer have led to an increased effort to
assess their potential across a wider range of solid and
hematological tumor types, including those for which
current treatment options are limited. Developments in
the use of immunotherapies in several cancers were dis-
cussed at the 2015 Spring and Winter meetings of the
Campania Society of Oncology Immunotherapy (SCITO)
and are reported here.
Non-small-cell lung cancer
Increased understanding of immune evasion strategies has
resulted in the development of novel immunotherapies,
including several agents that target PD-1 pathway. Both
anti-PD-1 and PD-L1 compounds are currently in active
clinical development for the treatment of non-small-cell
lung cancer (NSCLC) (Table 1).
Anti-PD-1 agents include pembrolizumab and nivolu-
mab, both of which have been approved by the US Food
and Drug Administration (FDA) for the treatment of
squamous or non-squamous NSCLC. As part of the
KEYNOTE-001 trial, 495 patients with previously treated
and treatment-naïve advanced NSCLC were treated with
pembrolizumab 2 mg/kg every three weeks or 10 mg/kg
every two weeks with a median duration of follow-up of
10.9 months [5]. Overall response rate (ORR) was 19.4 %
and median duration of response (DOR) was 12.5 months.
Median progression-free survival (PFS) was 3.7 months
and median overall survival (OS) was 12.0 months. In 204
patients evaluable by an immunohistochemistry (IHC)
clinical trial assay, ORR was 45.2 % in those with mem-
branous PD-L1 expression in ≥50 % of tumor cells
(proportion score [PS] ≥50 %), compared to 16.5 % in pa-
tients with PS 1–49 and 10.7 % in patients with PS < 1 %.
Among patients with a PS ≥ 50, median PFS was
6.3 months; median OS was not reached. The relationship
between ORR and PD-L1 expression was observed in both
previously treated and treatment-naïve patients. Pembroli-
zumab is being further investigated versus docetaxel in pre-
treated NSCLC patients with PD-L1 ≥ 1 %, showing in-
creased effectiveness both in terms of ORR and OS in pa-
tients with PD-L1 ≥ 50 % (KEYNOTE-010; NCT01905657)
[6], versus standard of care in treatment-naïve NSCLC pa-
tients with PD-L1 ≥ 50 % (KEYNOTE-024; NCT02142738)
and versus placebo in early-stage NSCLC after resection
and standard adjuvant therapy (PEARLS; KEYNOTE-091;
NCT02504372).
Nivolumab has also been shown to be effective and well
tolerated in patients with non-squamous NSCLC in phase
II/III studies [7, 8]. In addition, in the CheckMate 012
multi-arm phase I study of nivolumab, platinum doublet
plus nivolumab was promising with an ORR of 33–50 %,
24-week PFS of 36–71 % and 1-year OS of 59–87 % [9].
Similarly, nivolumab was effective compared with
docetaxel in patients with advanced non-squamous
NSCLC who had progressed during or after platinum-
based doublet chemotherapy [10]; median OS was
12.2 months with nivolumab (n = 292) versus 9.4 months
with docetaxel (n = 290) and the 1-year OS rate was 51 %
versus 39 %. ORR was 19 % with nivolumab versus 12 %
with docetaxel and median DOR was 17.2 versus
5.6 months. Almost one-quarter (24 %) of patients on
nivolumab were treated beyond RECIST v1.1-defined pro-
gression and a non-conventional benefit was observed in
16 patients (not included in best overall response). Nivolu-
mab was associated with greater efficacy than docetaxel
across all endpoints in subgroups defined according to
pre-specified levels of tumor-membrane PD-1 expression
(≥1 %, ≥5 %, and ≥10 %). Nivolumab has also shown
improved efficacy versus docetaxel in 272 patients with
advanced squamous-cell NSCLC [11]. Median OS was
9.2 months with nivolumab versus 6.0 months with doce-
taxel; risk of death was 41 % lower with nivolumab
(hazard ratio [HR] 0.59; 95 % CI: 0.44–0.79; p < 0.001). At
1 year, the OS rate was 42 % with nivolumab versus 24 %
with docetaxel. ORR was independent of PD-L1 expres-
sion and consistently higher for nivolumab versus
docetaxel.
The anti-PD-L1 agent durvalumab (MEDI4736) has also
shown encouraging antitumor activity and a manageable
safety profile in patients with NSCLC. In a phase I trial of
patients with various solid tumor types, disease control
rate (DCR) at 12 weeks was 41 % and ORR was 16 %
among 162 evaluable patients with NSCLC, with activity
observed in both squamous and non-squamous histolo-
gies [12]. ORR was higher in PD-L1+ than PD-L1− pa-
tients (25 % versus 10 %). Durvalumab is now being
assessed as sequential therapy in patients with locally ad-
vanced unresectable stage III NSCLC who have not pro-
gressed following platinum-based chemoradiation therapy
(PACIFIC trial, NCT02125461). Another PD-L1 inhibitor
in development is atezolizumab (MPDL3280A). In a phase
I dose-escalation and expansion study involving 88 pa-
tients, ORR was 21 % and 24-week PFS rate was 42 %
[13]. PD-L1 expression appeared to be predictive for clin-
ical benefit. No maximum tolerated dose, dose-limiting
toxicities or treatment-related deaths were observed, with
the majority of adverse events (AEs) grade 1–2. In interim
analysis from the randomized, phase II POPLAR trial of
previously treated NSCLC patients, median OS was
11.4 months with atezolizumab versus 9.5 months with
docetaxel (HR 0.78). Improved efficacy was observed with
increasing PD-L1 expression; patients with the lowest PD-
L1 did not appear to benefit from atezolizumab treatment
[14]. Fewer patients receiving atezolizumab experienced
grade ≥3 AEs and there were no unexpected toxicities.
Atezolizumab is being further assessed in PD-L1+ locally
advanced or metastatic NSCLC patients (BIRCH phase II
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Table 1 Overview of PD-L1 and PD-1 inhibitors currently in development
Compound Lead company Antibody type Affinity/K2 Selected tumour types assessed Biomarker status
Anti-PD-L1
Atezolizumab (MPDL3280A) Roche Engineered IgG1
(no ADCC)
0.4 nM NSCLC: ORR: 21 %; 24-week PFS rate: 42 % [9]
Median OS: 11.4 months (vs 9.5 with
docetaxel) [10]
PD-L1 tested with SP142 mAb clone, with an
automated system, and evaluated on both
tumoral and immune-infiltrate cells, with a
cut-off of ≥5 % and ≥10 %
Biomarker status still experimental
Durvalumab (MEDI4736) AstraZeneca Modified IgG1 (no ADCC) NA NSCLC: 12-week DCR: 41 %; ORR: 16 % [8]
HNSCC: ORR: 12 % (25 % in PD-L1+ patients);
24-week DCR: 16 % (25 % in PD-L1+ patients)
[43]
Currently being assessed in first-line recurrent
or metastatic HNSCC in combination with
tremelimumab [44].
Also being assessed as monotherapy or in
combination with tremelimumab in bladder,
gastric, pancreatic, HCC and blood cancers.
PD-L1 tested with SP263 mAb clone, with an
automated system, on tumoral cells, with a
cut-off of ≥25 %
Biomarker status still experimental
BMS-936559 Bristol-Myers Squibb IgG4 (humanised) NA Being assessed in NSCLC, melanoma,
and renal-cell cancer
PD-L1 tested with 28–8 mAb clone, with an
automated system, on tumoral cells, with a
cut-off of ≥5 %
Biomarker status still experimental
Anti-PD-1
Nivolumab Bristol-Myers Squibb IgG4 2.6 nM Approved in previously-treated advanced
squamous or non-squamous NSCLC and
RCC, metastatic melanoma, and HL that has
relapsed or progressed after HSCT and
post-transplantation brentuximab vedotin.
Platinum-resistant ovarian cancer: ORR: 23 %;
DCR: 54 % [25].
Advanced HCC: CR: 2/39 (5 %); PR 7/39 (18 %);
6-month OS: 72 % [32]
Heavily pretreated RR-HL: ORR: 87 %; CR: 22 %.
Mmedian DOR and median PFS not yet
reached at median follow up of 101 weeks
[53].
RR-DLBCL: ORR: 36 %; median overall DOR of
22 weeks [62].
RR-FCL: ORR: 40 %. At a median follow up of
91 weeks, the median DOR for responding
patients was not yet reached [62].
PD-L1 tested with 28–8 mAb clone, with an
automated system, on tumoral cells, with a
cut-off of ≥5 %
Biomarker status: No testing required
Pembrolizumab Merck & Co IgG4 (humanised) 29 pM Approved in previously-treated advanced
squamous or non-squamous NSCLC and
metastatic melanoma.
Ovarian cancer: ORR: 11.5 %, 23.1 % of
patients had evidence of tumor reduction;
DCR: 34.6 % [27].
PD-L1 tested with 22C3 mAb clone, with an
automated system, on tumoral cells, with a
cut-off of ≥1 % and ≥50 % (strong positive).















Table 1 Overview of PD-L1 and PD-1 inhibitors currently in development (Continued)
Esophageal cancer: ORR : 23 % (n = 5); best
response was SD in 18 % (n = 4) and PD in
59 % (n = 13) [30].
Advanced gastric cancer: ORR: 22 % (95 % CI:
10–39) by central review and 33 % (95 % CI:
19–50) by investigator review. Median time to
response was 8 weeks (range 7–16); median
DOR: 24 weeks; 6-month PFS: 24 % and
6-month OS: 69 % [31].
HNSCC: ORR (confirmed and unconfirmed):
18.2 % (95 % CI: 11.1–27.2) with 18 partial
responses and 31 with SD [39}.
Recurrent/metastatic nasopharyngeal
carcinoma: CR: 1/27; PR: 6/27; SD 14/27; The
best ORR (confirmed and unconfirmed):
25.9 % (95 % CI, 11.1–46.3) [42].
RR-HL: ORR: 65 %; CR: 16 %; median PFS at
24 weeks: 69 % with a median DOR
≥24 weeks in 71 % of patients who achieved
complete or partial response [54, 55].
AMP-224 GlaxoSmithKline PD-L2 IgG1 Fc fusion NA Being assessed in metastatic colorectal cancer
in combination with stereotactic body
radiation therapy.
Othera
Pidilizumab Medivation IgG1 (humanised) NA Relapsed/refractory DLBCL: CR:34 %; ORR:
51 % in patients with measurable disease
after transplant. In the whole cohort of
patients, 16-month PFS from first treatment:
72 %; OS >80 % [60]
Relapsed/refractory FCL in combination with
rituximab: ORR: 66 %; CR: 52 %;. Median PFS
for all patients:18.8 months, and not reached,
at time of analysis, for the 19 patients with
CR/PR
NR
ADCC antibody-dependent cell-mediated cytotoxicity, CR complete response, DCR disease control rate, DLBCL diffuse large B cell lymphoma, DOR duration of response, FCL follicular lymphoma, HCC hepatocellular
carcinoma, HL Hodgkin’s lymphoma, HNSCC head and neck squamous cell carcinoma, HSCT hematopoietic stem cell transplantation, mAb monoclonal antibody, NA not available, NSCLC non-small cell lung cancer,
ORR overall response rate, OS overall survival, PD progressive disease, PFS progression-free survival, PR partial response, RCC renal cell carcinoma, R/R relapsed/refractory, SD stable disease















study; NCT02031458) and versus docetaxel as second- or
third-line treatment in locally advanced or metastatic
NSCLC patients (OAK phase III study; NCT02008227).
Breast cancer
TILs have been consistently documented in breast cancer
(BC) and have been associated with prognosis. In a sem-
inal paper published in 1992, Aaltoma and colleagues re-
ported that lymphocytic infiltration was associated with a
good prognosis, but only among rapidly proliferating
tumors [15]. Similarly, the presence of TILs is observed in
some BCs and has been reported to be a potential
prognostic and predictive marker in some disease types,
especially triple-negative (TNBC) and HER2+ BC [16, 17].
Retrospective studies from (neo)-adjuvant trials have
evaluated whether TILs could identify patients with a
specific outcome. Denkert et al. have shown that TIL+ tu-
mors present a good outcome as opposed to their negative
counterparts [18, 19]. Based on this observation, the abil-
ity of TILs to quantify the residual risk of relapse after ad-
juvant treatment has been evaluated in two retrospective
analyses from randomized trials [17, 20]. More recently,
the association between TILs and pathological complete
response (pCR) has been further evaluated by Denkert
and colleagues [19, 21]. In the GeparSixto trial, increased
pCR rates were observed in TNBC and HER2+ BC with
high-TIL, compared with low-TIL tumors [19]. In the
NeoALTTO trial that randomized 455 women with HER2
+ early-stage BC to receive either trastuzumab or lapatinib
or both agents followed by the addition of weekly pacli-
taxel and three cycles of FEC after surgery, the presence
of TILs at diagnosis was an independent prognostic
marker for pCR and event-free survival [21].
In a retrospective study of 304 patients with TNBC
and residual disease after neoadjuvant chemotherapy,
both intratumoral and stromal TILs at surgery were as-
sociated with better prognosis, especially in patients with
large tumor burden (Fig. 1) [22]. Interestingly, in this
study 85 % of the samples with high-TIL after neoadju-
vant chemotherapy were low-TIL on core biopsies pre-
neoadjuvant chemotherapy. Also, the prognostic value of
TILs in TNBC has been recently confirmed by two
phase III adjuvant trials [23].
Moreover, in a pooled analysis of six clinical trials involv-
ing 991 patients with TNBC treated with anthracycline-
based chemotherapy, each 10 % increase in stromal TILs
was associated with a 14 % relative reduction in invasive
disease-free survival (IDFS) events (HR = 0.86, 95 % 0.80–
0.93, p < 0.0001) and a 17 % relative reduction in deaths
(HR = 0.83, 95 % CI 0.76–0.91, p = 0.0001) [24]. In a multi-
variate analysis adjusted for age, nodal status, tumor size
and chemotherapy regimen, the HR for each 10 % increase
in stromal lymphocytic infiltration was 0.86 (0.76–0.92) for
IDFS events and 0.84 (0.76–0.92) for death. Moreover,
stromal TILs added significant independent prognostic in-
formation for both IDFS (chi2 = 17.9; p < 0.0001 and OS
(chi2 = 16.7; p < 0.0001).
TILs may also be predictive of a better response to
treatment. In the BIG 02–98 trial, only in the HER2-
positive BC subgroup was there evidence of a heteroge-
neous treatment response according to the percentage of
TILs. In this subgroup, patients with high-TIL showed a
higher benefit to an immunogenic chemotherapy, such
Fig. 1 Prognostic value of tumor-infiltrating lymphocytes on residual disease after neo-adjuvant chemotherapy for triple-negative breast cancer.
[22] Estimated Kaplan–Meyer curves of metastasis-free survival a and overall survival b for all patients
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as anthracyclines, as compared to those with low-TIL tu-
mors [20].
In the FinHER trial, 232 patients with HER2+ disease
were randomized to nine weeks of chemotherapy with
or without trastuzumab [17]. Each 10 % increase in TILs
was significantly associated with decreased distant recur-
rence in patients receiving trastuzumab. However, ex-
ploratory analyses from a subset of HER2+ patients in
the N9831 study indicated that stromal TILs were asso-
ciated with improved recurrence-free survival in patients
treated with chemotherapy alone but not in patients
treated with chemotherapy plus trastuzumab [25].
Evidence that a positive TIL status is associated with
better outcome supports the development of immuno-
therapeutic strategies in patients with BC. In addition,
evaluation of lymphocytic infiltrate status could help
identify a subset of TIL− patients with TNBC or HER2+
BC who warrant additional therapy. Also, the ability to
convert TIL− tumors into TIL+ tumors needs further in-
vestigation; such an approach might allow selecting
which patients with TIL- TNBC are candidates for novel
therapies in the (neo)-adjuvant setting.
Ovarian cancer
Despite advances in combination chemotherapy regi-
mens, current options for ovarian cancer patients are in-
adequate and the majority of patients will relapse. An
important factor in the poor outcomes seen in patients
with ovarian cancer is the lack of effective second-line
treatments. As such, novel therapies need to be integrated
into treatment strategies to achieve durable clinical out-
comes. Immunotherapy offers a novel and promising
therapeutic strategy.
Evidence for an immune role in ovarian cancer is shown
by the observation that the presence of CD3+ and CD8+
TILs is associated with favorable OS in ovarian cancer. In
addition, several tumor-associated antigens (TAAs) that
are up-regulated in tumor tissue and ascites of ovarian
cancer patients have been identified (e.g., Her2/neu, folate
receptor α, p53, CA125, and members of the cancer-testis
antigen family such as MAGE -A4 and NY-ESO-1). Poten-
tial immunotherapeutic approaches in ovarian cancer
include monoclonal antibodies, immune checkpoint in-
hibitors, vaccines and adoptive cell therapy (ACT).
Antibodies include catumaxomab, a trifunctional bispe-
cific (anti-EpCAM/anti-CD3) antibody that has been
shown to improve puncture-free interval in heavily pre-
treated patients with chemotherapy-refractory ovarian
cancer and recurrent symptomatic malignant ascites [26],
the anti-EGFR agents cetuximab and panitumumab [27,
28], and antibodies that target tumor-associated macro-
phage (e.g., anti-CCL22, anti-B7-H4, anti-CSF-1R).
Checkpoint inhibitors are also being investigated in
ovarian cancer. PD-L1 expression on monocytes in the
ascites and blood of patients with ovarian cancer corre-
lates with poor clinical outcome and cytotoxicity assays
have revealed that PD-L1 overexpression on murine
ovarian cancer cells inhibits cytotoxic T lymphocyte
(CTL) degranulation and reduces CTL-mediated tumor
lysis. In the first trial of nivolumab in patients with
platinum-resistant ovarian cancer (n = 15), treatment re-
sulted in a response rate of 23 % and DCR of 54 % [29].
In follow-up of two patients with complete response and
one with a partial response, antitumor responses were
durable and continued after discontinuation of nivolu-
mab [30]. Pembrolizumab is also being assessed in ovar-
ian cancer. In the ongoing non-randomized, phase Ib
KEYNOTE-028 trial in patients with PD-L1+ solid tu-
mors, pembrolizumab showed antitumor activity in an
interim analysis of the patient cohort with heavily pre-
treated metastatic ovarian cancer (n = 26); ORR was 11.5 %,
23.1 % of patients had evidence of tumor reduction and
DCR was 34.6 % [31]. Treatment was also generally well
tolerated with no discontinuations due to toxicities. The
anti-PD-L1 antibody, avelumab (MSB0010718C), has also
shown promising results in ovarian cancer. In a phase Ib,
open-label expansion trial, four of 23 patients (17.4 %)
followed-up for ≥2 months achieved an partial response, 11
(47.8 %) had stable disease, and two had >30 % tumor
shrinkage after progression was reported [32]. Median PFS
was 11.9 weeks and PFS rate at 24 weeks was 33.3 % (95 %
CI 11.5–57.2). The safety profile was acceptable, with fa-
tigue, nausea, and diarrhea the most commonly reported
drug-related AEs, and phase III studies are ready to start in
first-line and platinum-sensitive recurrence.
Another possible approach is targeting the indolea-
mine 2,3-dioxygenase (IDO) pathway, an important
mechanism of tumor-related immunosuppression. In
ovarian cancer, IDO expression is prevalent in >50 % of
surgically resected tissue, correlates with a reduced
number of CD8+ TILs and NK cells, promotes tumor
angiogenesis and is positively associated with impaired
survival in serous-type disease. The first IDO-targeted
therapy is 1-methyl-tryptophan (1-MT), a small mol-
ecule inhibitor of IDO, that prolonged survival when
added to paclitaxel in an IDO-overexpressing murine
ovarian cancer model and that is being evaluated in
phase I clinical trials in different solid tumors with en-
couraging results.
Vaccine strategies in ovarian cancer include Cvac, an ex
vivo dendritic cell vaccine that has shown promise in a
phase II study in 63 patients in second remission [33], an
in vivo dendritic cell vaccine based on the MSLN-Hsp70
fusion protein, peptide vaccines, and recombinant viral
vaccines that utilize genetically modified viruses as vectors
for introducing TAA-encoding DNA into cells within the
body e.g., PANVAC-VF. Finally, ACT, a process that
involves using autologous or allogeneic antitumor
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lymphocytes to induce cancer regression may have a role
with the activation of endogenous T-cell immunity having
been induced to enhance the elimination of tumor cells
and the development of tumor-specific memory responses
in a mouse model of ovarian cancer. Multiple ovarian-
specific tumor antigens are being used in chimeric antigen
receptor (CAR) development and ACT strategies are mov-
ing towards the clinic.
As in other cancers, the use of combination immuno-
therapeutic strategies is likely to be important in ovarian
cancer. Strategies being investigated include anti-CTLA-4
and GVAX, a granulocyte-macrophage colony-stimulating
factor (GM-CSF) gene-transfected tumor cell vaccine and
nivolumab and an IDO inhibitor (INCB24360). Identifica-
tion of the optimal treatment combinations should trans-
late to substantial improvements in long-term clinical
benefit.
Gastrointestinal cancer
Despite some recent improvements, the prognosis for
advanced gastric and esophageal cancer remains poor,
with limited treatment options in the metastatic or unre-
sectable setting and a typical median survival of less than
one year. As with many other cancer types, immune
checkpoint inhibitors may provide a new therapeutic op-
tion in the treatment of gastrointestinal (GI) neoplasms.
PD-L1 is frequently overexpressed in esophageal can-
cer and may be associated with a poor prognosis. In a
preliminary analysis of the non-randomized, phase Ib
KEYNOTE-028 trial of pembrolizumab for PD-L1+ ad-
vanced solid tumors, 90 patients with esophageal cancer
were screened of whom 37 (41 %) had PD-L1+ tumors
[34]. In the 23 patients treated to date, ORR (confirmed
and unconfirmed) was 23 % (n = 5); the best response
was stable disease in 18 % (n = 4) and progressive disease
in 59 % (n = 13). Six patients (26 %) experienced drug-
related AEs, including two (9 %) with grade 3 events.
There were no grade 4 events and no patients died or
discontinued due to an AE.
In the KEYNOTE-012 trial, the safety and efficacy of
pembrolizumab was assessed in patients with PD-L1+
advanced gastric cancer [35]. Of the 162 patients
screened, 65 (40 %) were PD-L1+ and 39 were treated
with a median follow-up of 8.8 months (range 6.2–12.6).
ORR was 22 % (95 % CI: 10–39) by central review and
33 % (95 % CI: 19–50) by investigator review. Median
time to response was 8 weeks (range 7–16), with a
median DOR of 24 weeks. The 6-month PFS rate was
24 % and 6-month OS was 69 %. PD-L1 expression level
was associated with ORR. Treatment was well tolerated
with four patients experiencing grade 3/4 drug-related
AEs. Pembrolizumab is being further evaluated alone or
in combination with chemotherapy in the phase II
KEYNOTE-059 study of patients with recurrent or
metastatic gastric or gastroesophageal junction adeno-
carcinoma (NCT023354110) and as second-line therapy
in the phase III KEYNOTE-061 study versus paclitaxel
in patients with advanced gastric or gastroesophageal
junction adenocarcinoma after progression on chemo-
therapy (NCT02370498).
Hepatocellular carcinoma
The prognosis for hepatocellular carcinoma (HCC) is
generally poor given the low effectiveness of available
treatments and the overall 5-year survival rate is ap-
proximately 5–6 %. Immunotherapeutic interventions
may represent a novel and effective approach, although
only few immunotherapy trials for HCC have been con-
ducted and results to date have been modest.
Nivolumab was assessed in a phase I/II trial in patients
with advanced hepatocellular carcinoma [36]. Drug-
related AEs of any grade occurred in 29 of 41 patients
(71 %); 17 % of patients had grade 3/4 AEs. A dose-
limiting toxicity occurred in an uninfected patient re-
ceiving nivolumab 10 mg/kg but no maximum tolerated
dose was defined. Response was evaluable in 39 patients;
two had a complete response (5 %) and seven had partial
responses (18 %); responses were durable. OS rate at
6 months was 72 %.
Another potential option for HCC is the development
of vaccines, including pulsed dendritic cell-based vaccines
and peptide vaccines. The first HCC vaccine tested was
based on CD8+ T-cell epitopes specific for α-fetoprotein
(AFP), showing the generation of AFP-specific T-cell re-
sponses in vaccinated subjects [37]. The same group also
conducted a subsequent phase I/II trial administering AFP
epitopes presented by autologous dendritic cells loaded ex
vivo; however, this only produced a transient CD8+ T-cell
responses, possibly caused by the lack of CD4+ support
[38]. To increase the number of tumor TAAs elicited by
the vaccine, approaches using autologous dendritic cells
pulsed ex vivo with a lysate of the autologous tumor [39]
or of hepatoblastoma cell line HepG2 [40] have been eval-
uated in clinical trials. However, results have been
unsatisfactory.
One explanation for the limited success of HCC vac-
cines to date is that the liver is an inherently immuno-
suppressive microenvironment, a state that may be
further exacerbated by chronic inflammation due to
hepatitis infection (Fig. 2). Moreover, TAAs used in such
clinical trials are not HCC-specific. In order to improve
the efficacy of HCC vaccines, new and more specific
TAAs and/or tumor epitopes need to be identified, both
HLA class I and II restricted, aiming at inducing CD4+
as well as CD8+ activation. In addition, improved im-
mune responses elicited by HCC vaccines may be
achieved by adjuvant strategies that increase the im-
munogenicity of the vaccine antigen and/or counteract
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the immunosuppressive tumor environment. These in-
clude combination approaches with chemotherapy or
loco-regional treatments (e.g., tumor ablation, transar-
terial chemoembolization [TACE]), the use of novel im-
munomodulatory adjuvants, and delivery systems that
increase antigen presentation (e.g., biodegradeable nano-
particles as antigen carriers) [41].
An important initiative in the development of a vac-
cine for HCC is the EU-supported HEPAVAC project
(www.hepavac.eu), aiming at developing a novel thera-
peutic HCC vaccine with multiple TAAs that are pre-
sented on the surface of primary HCC cells. This will
involve on an ‘off-the-shelf ’ vaccine comprising 18 newly
identified MHC-I and II tumor-associated peptides
(TUMAPs) naturally processed and presented on pri-
mary tumor tissues from HCC patients together with an
actively personalised vaccine (APVAC) approach involv-
ing patient-specific mutated peptides. Both vaccines will
be combined with a novel and potent RNA-based immu-
nomodulator (RNAdjuvant®). Feasibility, safety and
biological efficacy will be evaluated in a randomized,
controlled multicentre phase I/II clinical trial, and will
hopefully result in the first multi-epitope, multitarget
and multi-HLA allele therapeutic cancer vaccine for this
frequent and aggressive disease [42].
Head and neck cancer
Treatment options for recurrent/metastatic head and neck
squamous cell carcinoma (HNSCC) remain poor with a
median OS of 10 months in the first-line setting and
6 months in previously treated patients. Human papillo-
mavirus (HPV) is recognized as the causative agent of
HNSCC in a growing subset of patients. Prominent im-
mune escape during malignant progression is observed in
HNSCC, with the PD-1/PD-L1 pathway playing an im-
portant role. The majority of HPV+ and a subset of HPV−
HNSCC tumors are PD-L1+. Thus, blocking PD-1 inter-
action with PD-L1 or PD-L2 may reactivate immune
surveillance and elicit antitumor activity.
Pembrolizumab has demonstrated antitumor activity in
multiple tumor types, including HNSCC. The KEYNOTE-
012 phase 1b multi-cohort study in patients with advanced
Fig. 2 Limiting factors in immune-based approaches in hepatocellular carcinoma [f41]
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solid tumors included a HNSCC expansion cohort with
132 patients irrespective of PD-L1 or HPV status who re-
ceived fixed-dose pembrolizumab 200 mg every three
weeks [43]. In 99 patients available for preliminary efficacy
analysis, ORR (confirmed and unconfirmed) was 18.2 %
(95 % CI: 11.1–27.2) with 18 partial responses and 31 with
stable disease. Pembrolizumab was active in both HPV+
and HPV− patients. Drug-related AEs of any grade oc-
curred in 47 % of patients and drug-related grade ≥3 AEs
occurred in 7.6 %. In a further evaluation of immune-
related gene expression patterns in 43 of these patients, the
‘Interferon-γ (IFN-γ) 0 10-gene’, ‘expanded-immune 28-
gene’ and ‘de novo’ signatures showed significant associa-
tions with ORR and PFS.
In the expansion cohort of the phase Ib KEYNOTE-
028 trial, the antitumor activity of pembrolizumab
10 mg/kg every two weeks is being assessed in patients
with PD-L1+ recurrent/metastatic nasopharyngeal car-
cinoma (NPC). PD-L1 expression in NPC is upregulated
by Epstein-Barr virus (EBV) induced activation of LMP1
and IFN-γ pathways and PD-1/PD-L1 expression may
correlate with poor prognosis [44, 45]. Among 27 pa-
tients, one had a complete response, six had partial re-
sponses and 14 had stable disease. The best overall
(confirmed and unconfirmed) response rate was 25.9 %
(95 % CI, 11.1–46.3) [46]. Pembrolizumab was well tol-
erated with drug-related AEs observed in 70.4 % of pa-
tients. This represents the first demonstration of
antitumor activity of a PD-1 inhibitor in recurrent/meta-
static NPC and further investigation is planned.
Durvalumab is also being assessed in HNSCC, in an
ongoing open-label, phase I/II study in multiple solid
tumor types [47]. In 51 of 62 HNSCC patients evaluable
for response with ≥24 weeks of follow-up, ORR was
12 % (25 % in PD-L1+ patients), and DCR at 24 weeks
was 16 % (25 % in PD-L1+ patients). Drug-related AEs
were observed in 60 % of patients, with fatigue, diarrhea,
and nausea the most frequent. Grade ≥ 3 drug-related
AEs were reported in 7 % of patients: rash (n = 2), and
increased GGT, fatigue, and tumor inflammation (n = 1
for each). Durvalumab is also being assessed in combin-
ation with the CTLA-4 inhibitor tremelimumab versus
standard of care for the treatment of first-line recurrent
or metastatic HNSCC [48].
Lymphomas
Application of immunotherapy to the management of
lymphomas poses unique challenges and opportunities
since these malignancies originate from the immune sys-
tem itself [49]. Lymphomas represent the fifth most
common cancer in developed countries and collectively
display an age-adjusted incidence of about 23 cases per
100,000 individuals. In the Western world, the greatest
majority of lymphoid malignancies arise from mature B
cells that, throughout the complex pathway to generate
cells producing antibodies with a high specificity and
avidity, accumulate genetic and epigenetic changes in-
compatible with their proper function. Studies have
shown that most B cell non-Hodgkin lymphomas (NHL)
and Hodgkin lymphoma (HL) derive from these non-
functional B cells escaping the apoptotic death within
secondary lymphoid tissues [50]. Similar mechanisms,
involving errors in the generation of a functionally active
T-cell receptor have been implied in the pathogenesis of
the more rare T-cell NHLs [50]. The cellular and clinical
heterogeneity of lymphomas reflects the complexity of
the human immune system including the intricate pat-
terns of cellular interplay underlying the functional regu-
lation of the immune response. Beyond the focus on the
genetic changes and cell-signaling aberrations that may
act as targets for a tailored therapeutic intervention
across the various lymphoma subtypes, studies have re-
cently recognized that mechanisms operated by lymph-
oma cells to evade antitumor immunity through the
generation and maintenance of a tolerogenic tumor
microenvironment can represent a further area to build
newer immunotherapeutic approaches [51, 52].
Among these strategies, immune checkpoint inhibition
is emerging with considerable promise in the treatment
of NHL and HL. However, at variance with solid tumors,
lymphomas are characterized by a more promiscuous
pattern of reciprocal expression of the receptor-ligand
pairs of the PD-1 pathway among tumor cells and non-
malignant lymphoid cells. These expression patterns are
also significantly variable across the specific lymphoma
subtypes [53]. The expression of PD-L1/2 on tumor cells
can be regulated by IFN-γ, IL-4 and other cytokines pro-
duced in the tumor environment typical of some lymph-
omas, while, in other lymphoma subtypes, the constitutive
expression of PD-L1/2 on tumor cells is related to a spe-
cific acquired genetic trait. Tumor cells of some lymph-
oma subtypes do not directly express PD-1-L, but PD-L1+
histiocytes and other microenvironmental cells are present
which contribute to the exhaustion of tumor PD-1+ infil-
trating T/NK cells. As an example, while in HL and some
biologically related NHL, such as the primary mediastinal
B-cell lymphoma (PMBCL), tumor cells clearly overex-
press PD-L1/2, in follicular cell lymphoma (FCL), the
prototype of indolent NHL, malignant cells are usually
negative for expression of both PD-1 ligands. In aggressive
NHL, the patterns of expression of PD-1 and its ligands in
tumor cells might not differ from their non-malignant
counterpart cells or display a subtype-divergent picture as
in the case of the germinal-center (GC) and activated B cell
(ABC) variants of diffuse large B-cell lymphoma (DLBCL).
Such heterogeneity depends on specific genetic features ac-
quired by tumor cells, the variable milieu of cytokine-
mediated and cell contact-dependent interactions among
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malignant and non-malignant cell populations within the
lymphoma microenvironment or on the combination of all
these factors.
Hodgkin’s lymphoma
PD-L1 and/or PD-L2 over-expression on lymphoma cells
may play a critical role in immune evasion in patients
with HL. The PD-L1 and PD-L2 genes are located on
chromosome 9p24.1, over-amplification of which repre-
sents a specific structural alteration that occurs in some
cases of HL; this increases the gene dosage of PD-1 li-
gands as well as their induction by JAK2 whose gene is
located in the same amplified chromosomal trait [54].
As such, the PD-1 pathway and JAK2 may represent
complementary therapeutic targets in HL (Fig. 3). How-
ever, tumor cells from HL cases with normal 9p24.1
copy numbers also appear to over express PD-1 ligands.
The presence of an AP-1–responsive enhancer in the
PD-L1 gene along with the constitutive AP-1 activation,
typical of tumor cells of HL, may then depict an alterna-
tive mechanism leading to PD-1 ligand overexpression
in this lymphoma [55]. Finally, the demonstration that
the EBV-encoded latent membrane protein 1 increases
PD-L1 promoter activity supports a third mechanism for
PD-L1 overexpression in HL, since EBV-encoded pro-
teins can be found in about 40 % of HL cases [55]. Such
concurrency of mechanisms may explain why overex-
pression of PD1-ligands is a phenotypic trait common to
almost all cases of HL. While this situation clearly ac-
counts, from one side, for the impressive clinical efficacy
of PD1-inhibitors in HL, it may hamper, from the other,
the use of PD-L1/2 expression on tumor cells as a pre-
dictive biomarker for response.
The therapeutic use of PD-1 inhibitors, nivolumab and
pembrolizumab, in patients with relapsed and refractory
(RR) HL has been initially explored in two early-phase
studies. In the expansion cohort of the phase Ib trial
(CA209-039), 23 patients with heavily pretreated RR-
HL were given nivolumab 3 mg/kg every two weeks until
response, tumor progression or intolerable side-effects
[56]. Of the enrolled patients, 78 % had progressed after
autologous stem cell transplantation (ASCT) and 78 %
had failed on brentuximab vedotin (BV). ORR was 87 %
with a complete response rate of 22 %. At a median fol-
low up of 101 weeks, the median DOR and median PFS
were not yet reached [57]. Nivolumab was overall well-
tolerated with few grade 3/4 toxicities, mostly involving
blood, skin, the gastrointestinal tract and lungs. Interest-
ingly, in the one patient that was retreated with nivolumab
post-progression, a second response was achieved. Ana-
lysis of pretreatment tumor specimens from 10 patients
revealed copy-number gains and increased expression for
Fig. 3 Mechanisms leading to PD1 ligands expression in Hodgkin Reed-Sternberg (HRS) cells of Hodgkin Lymphoma. Multiple mechanism are concurrently
implicated in overexpression of PD1-ligands by tumor cells of Hodgkin lymphoma. 1) Amplification of 9p24 increases gene dosage for PD-L1/2 and JAK2.
2) JAK2 gene product increases transcription of the PD-L1 gene. 3) HRS cells display the constitutive activation of AP1 whivh binds to an AP-1–responsive
enhancer in the PD-L1 gene. 4) The Epstein-Barr Virus (EBV)-encoded latent membrane protein 1 increases PD-L1 promoter activity, also via AP-1. 5) The
network underlying tumor microenvironment formation and maintenance in Hodgkin lymphoma results in the constitutive production of cytokines known
to enhance activity of the PD-L1 gene
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both PD-L1 and PD-L2. Within the Checkmate 205 pro-
gram, the CA209-205 study in RR-HL has recently com-
pleted the accrual for the original three cohorts, involving
more than 250 patients, and a further cohort is being
opened to test upfront treatment with single agent nivolu-
mab followed by a nivolumab/AVD (doxorubicin, vinblast-
ine, dacarbazine) combination for chemo-naïve patients
with advanced HL.
In the HL cohort of the KEYNOTE-013 study, 31
patients with RR-HL, who had progressed after BV and
67 % of whom had also failed ASCT, received pembroli-
zumab (10 mg/kg every 2 weeks) [58, 59]. The ORR was
65 % with a CR rate of 16 %. The median PFS at
24 weeks was 69 % with a median DOR ≥24 weeks in
71 % of patients who achieved complete or partial re-
sponse (range: 0.14–74+ weeks). There were no AEs of
grade higher than 3 and the most common treatment-
related AEs were hypothyroidism (16 %), diarrhea
(13 %), nausea (13 %), and pneumonitis (10 %). Based on
these impressive response rates and significant response
duration, a number of further trials involving PD-1-
(e.g., nivolumab, pembrolizumab) and PD-L1- (durvalu-
mab) targeted antibodies have been activated in patients
with RR-HL. Furthermore, combinations of anti-PD1
antibodies with other immune checkpoints inhibitors
such as ipilimumab and with BV are being currently
tested in the same patient setting. The combination of
PD-1 inhibitors with BV appears particularly intriguing
since the sustained clinical response achieved with this
latter agent, an anti-CD30 antibody conjugated with
monomethyl-auristatin E, a toxic poison of the dolastin
family, have been related, beyond its direct cytotoxic ac-
tivity, to the stimulation of an anticancer immune re-
sponse [60]. In an immunocompromised murine model,
therapeutic synergies were observed when combining
dolastatins with tumor antigen-specific vaccination or
PD-1/PD-L1 and CTLA-4 blockade [61]. This provides a
strong rationale for treatment strategies that combine
BV with immune-based therapies in patients with HL.
Non-Hodgkin lymphoma
In this group of lymphomas, the more heterogeneous
pattern of PD-1 and its ligands on tumor cells may ren-
der more complex the interpretation of early clinical re-
sults obtained with some of the immune checkpoint
inhibitors. One exception is represented by PMBCL,
since in this aggressive NHL tumor cells often share the
9p24.1 amplification and constitutive PD-L1/2 overex-
pression typical of HL [54]. In this regard, the PMBCL
cohort of KEYNOTE-013 study enrolled 10 heavily pre-
treated patients who also relapsed after or were ineligible
for ASCT [62]. In nine evaluable patients, the ORR was
44 %, with one patient achieving a CR and three patients
achieving a partial response. At a median follow-up of
144 days, the median DOR was not reached (1+ to 291+
days), with all four responses ongoing at the time of data
cutoff. These preliminary results fully justify further
studies in this unique type of NHL.
Within the aggressive lymphomas, DLBCL represents
the most common form accounting for about 30 to 35 %
of all NHL in the adults. Based on specific molecular
signatures, two main biological subtypes with a different
prognosis have been identified. In the GC-type of
DLBCL, tumor cells rarely express PD-L1/2 or PD-1 and
the presence of PD-1+ T cells in the microenvironment
is of unusual occurrence [53, 63]. Conversely, in DLBCL
of ABC-type, neoplastic cells are characterized by a
more sustained expression of PD-L1/2, but not of PD-1,
and an excess of PD-1+ T cells can be found in the
tumor microenvironment in some cases [53, 63]. In both
CG- and ABC-DLBCL, however, variable amounts of
PD-L1 and/or PD-1-expressing monocytes, histiocytes,
dendritic cells and T/NK cells can be found in the
microenvironment, supporting the presence of PD-1-
mediated interactions in the immune networks operating
in these tumors [53].
In a first single-arm phase 2 study, 66 eligible patients
with RR-DLBCL, were given pidilizumab (1.5 mg/kg every
42 days) in the attempt to prevent early progression in
those showing overt residual disease after ASCT and to
consolidate response in those who achieved a complete re-
sponse after transplantation [64]. Treatment yielded to a
CR rate of 34 % and ORR of 51 % among patients with
measurable disease after transplant. In the whole cohort
of patients a 16-month PFS from first treatment of 72 %
was recorded along with an OS exceeding 80 %. These fig-
ures met the primary study endpoints and a concurrent,
hypothesis-generating, immunoprofiling of circulating
cells was consistent with an ‘on-target ‘in vivo effect of
pidilizumab. No data were available as to relative frequen-
cies of GC- versus ABC-DLBCL subtypes within the ac-
crued patient population. Of note, it has recently been
revealed that the target of pidilizumab is not, as was ori-
ginally thought, PD-L1. Although its exact mechanism of
action has not yet been explained, it has been stated that
its administration is associated with enhanced maturation
and survival of T lymphocytes, which may improve adap-
tive immunity, as well as activation of natural killer cells,
which may improve innate immunity [65]. In the expan-
sion cohort of the CA209-139 nivolumab study in lymph-
oid malignancies, 10 RR-DLBCL patients, failing after or
ineligible for ASCT, were enrolled [66]. The ORR was
36 % and a complete response was obtained in two pa-
tients, with a median overall DOR of 22 weeks.
FCL, beyond representing the second most common
form of NHL in the Western world (22-25 % of all
cases), may be of particular interest in the setting of im-
mune checkpoint blockade strategies. Several molecular
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studies have confirmed that specific ‘immune signatures’,
mirroring the presence and activity of several types of
immune effectors in the lymphoma microenvironment,
may strongly and independently predict prognosis in this
indolent lymphoma [67]. In addition, while tumor cells
do not usually express PD-L1 or PD-1, the FCL micro-
environment is highly enriched for PD-1 and/or PD-L1/
2 immune effectors [53]. In a single-arm phase 2 study,
29 eligible patients with RR-FCL, all previously exposed
to rituximab, were treated with four courses of pidilizu-
mab (3 mg/kg every 4 weeks) followed by eight monthly
optional infusions in patients showing at least a stable
disease [68]. After 17 days from the first infusion of pidi-
lizumab, patients also received four weekly doses
(375 mg/m2) of rituximab. The combination of pidilizu-
mab plus rituximab was very well tolerated and devoid
of grade 3 and 4 adverse events. Of the enrolled patients,
19 (66 %) achieved an objective response, that was
complete in 15 (52 %). The median PFS for all patients
was of 18.8 months, and was not reached, at time of
analysis, for the 19 patients in complete or partial re-
sponse after pidilizumab plus rituximab. A concurrent
immunoprofiling study, confirmed the ‘on target’ activity
of the combination. The expansion cohort of the
CA209-139 nivolumab study enrolled 10 patients with
RR-FCL [66]. Four patients (40 %) achieved an objective
response, including a complete response and four partial
responses. At a median follow up of 91 weeks, the me-
dian DOR for responding patients was not yet reached.
The favorable toxicity profile of nivolumab was con-
firmed in these patients.
These extremely promising results are prompting an
increasing number of trials targeted to specific NHL
subtypes to better establish activity and mechanism of
action of different immune checkpoint inhibiting-agents
within such a heterogeneous group of tumors. Studies
are also being launched to test newer combinations with
antibodies targeting CD20 and other surface structures
of tumor B cells and with molecules which target the
known cell-signaling aberrations of the various NHL
subtypes. The outstanding results obtained in patients
with RR-HL led to the accelerated approval of nivolu-
mab in the US and to its ongoing registration in Europe,
where patient-named programs with this agent are cur-
rently ongoing. Studies testing the introduction of im-
mune checkpoint inhibitors for the upfront treatment of
HL have already been launched.
Conclusions
Treatment strategies that target the immune system pro-
vide the opportunity for antitumor activity across mul-
tiple cancer types, regardless of mutational status or
tumor histology. While many of the initial advances in
immunotherapy have been in melanoma, the focus has
now broadened to include many other solid as well as
hematological cancers. Different immunotherapeutic ap-
proaches are being evaluated across tumor types and
their various novel mechanisms of action and safety pro-
files offer the potential for a variety of combination regi-
mens. Ongoing and planned investigation of these
immunotherapies, alone and in combination, represents
the start of a new chapter in our treatment of cancer
and offers the hope of better outcomes for patients with
a wide range of cancers.
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